Amphastar Pharmaceuticals (AMPH) Other Operating Expenses (2013 - 2026)

Amphastar Pharmaceuticals has reported Other Operating Expenses for 14 years, with the latest figure at $13.3 million in Q2 2026.

• On a quarterly basis, Other Operating Expenses rose 30.29% year-over-year to $13.3 million in Q2 2026; TTM through Jun 2026 was $52.4 million, a 19.65% increase from a year earlier, with the FY2025 full-year figure at $43.9 million, up 16.09% from the prior year.
• Other Operating Expenses was $13.3 million for Q2 2026 at Amphastar Pharmaceuticals, up from $11.9 million in the prior quarter.
• The five-year high for Other Operating Expenses was $16.9 million in Q3 2025, with the low at $4.8 million in Q3 2022.
• Average Other Operating Expenses over 5 years is $9.2 million, with a median of $9.8 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Other Operating Expenses surged 76.12% in 2024, then decreased 1.39% in 2025.
• Over 5 years, Other Operating Expenses stood at $5.5 million in 2022, then soared by 57.51% to $8.6 million in 2023, then increased by 20.94% to $10.4 million in 2024, then fell by 1.39% to $10.3 million in 2025, then grew by 29.73% to $13.3 million in 2026.
• The last three Other Operating Expenses figures came in at $13.3 million (Q2 2026), $11.9 million (Q1 2026), and $10.3 million (Q4 2025), per Business Quant data.